SCHEMBL17612852

SCHEMBL17612852

CCOC(=O)[C@H]1CCCN(c2ccc(NS(=O)(=O)c3c(C)c(C)cc(C)c3C)c3ccccc23)C1

nearest known ligand 0.71

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 7/20 0.71
▸ NFE2L2 Q16236 1/20 0.71
▸ NPSR1 Q6W5P4 3/20 0.55
▸ TSHR P16473 2/20 0.55
▸ CYP2C19 P33261 1/20 0.46
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ APAF1 O14727 1/20 0.46
▸ ALDH1A1 P00352 4/20 0.46
▸ SHMT2 P34897 1/20 0.45
▸ HSD17B10 Q99714 2/20 0.45
▸ MAPK1 P28482 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17599447 1.00 KEAP1 (0.71) KEAP1NFE2L2NPSR1TSHRCYP2C19
SCHEMBL17612859 1.00 KEAP1 (0.71) KEAP1NFE2L2NPSR1TSHRCYP2C19
SCHEMBL17599417 0.89 KEAP1 (0.89) KEAP1NFE2L2NPSR1TSHRMEN1
SCHEMBL17599434 0.89 KEAP1 (0.89) KEAP1NFE2L2NPSR1TSHRMEN1
SCHEMBL17599488 0.89 KEAP1 (0.89) KEAP1NFE2L2NPSR1TSHRMEN1
SCHEMBL17599436 0.88 KEAP1 (0.74) KEAP1NFE2L2NPSR1TSHRMEN1
SCHEMBL17599548 0.86 NPSR1 (0.53) KEAP1NFE2L2NPSR1TSHRCYP2C19
SCHEMBL17612858 0.85 KEAP1 (0.81) KEAP1NFE2L2NPSR1TSHRMEN1
SCHEMBL17599442 0.83 KEAP1 (1.00) KEAP1NFE2L2MEN1KMT2AALDH1A1
SCHEMBL17599452 0.83 KEAP1 (1.00) KEAP1NFE2L2MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2997966-A1 Naphthyl Sulfonamide Pyrrolidine Derivatives as KEAP-1 Modulators for the Treatment of Diabetes, Obesity, Dyslipidemia and Related Disorders SANOFI (FR) 2016-03-23 — — EP disclosed
Send feedback